6533b85dfe1ef96bd12bf25b
RESEARCH PRODUCT
LDL size: does it matter?
Rizzo ManfrediK. Berneissubject
AdultMalemedicine.medical_specialtyArteriosclerosisCoronary DiseaseCohort Studieschemistry.chemical_compoundHigh-density lipoproteinSex FactorsRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusPrevalenceAnimalsHumansatherogenic lipoprotein phenotypeProspective Studiescoronary heart diseaseRisk factorsmall dense LDLTriglyceridesAgedHypolipidemic AgentsMetabolic SyndromeClinical Trials as Topicdiabetesbusiness.industryCholesterolSmokingAge FactorsGeneral MedicineCholesterol LDLAtherogenic lipoprotein phenotypeMiddle Agedmedicine.diseasePhenotypeLipoproteins LDLEndocrinologyLogistic ModelsPhenotypechemistryLow-density lipoproteinFemaleMetabolic syndromeInsulin Resistancebusinessdescription
The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2004-12-11 | Swiss medical weekly |